New research presented at this year’s European Congress on Obesity (held online, 10-13 May) shows that the obesity drug semaglutide reduces appetite, food cravings and energy […]
An early study of a new experimental drug to treat obesity known as cagrilintide shows that, when combined with semaglutide 2.4 mg, the combination leads to […]
New research presented at this year’s European Congress on Obesity (held online 10-13 May) has found a reduced risk of eye cataracts occurring in patients who […]
The STEP trials published over the past year have established the efficacy and safety of semaglutide in treating patients with obesity. A new study analysing the […]